drugset / Trial / NCT00697749
Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 Genotype
RandomizedParallel-groupOpen-labelPrevention
Summary
This study compares the immunogenicity and safety of the novel adjuvanted HBV vaccine and Engerix™-B administered to subjects who were positively identified as having the HLA-DQ2 genotype
Timeline
- Start
- 1999-04
- Primary completion
- 2000-01
- Completion
- 2000-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Engerix-B | Vaccine | — | Intramuscular |
| Subject | HBV-MPL vaccine 208129 | Vaccine | — | Intramuscular |